Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 15

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 15
---
 value or even maintain
the price at which the shareholders have purchased their shares.

| S-8 |

### USE OF PROCEEDS
We may issue and sell our common shares having aggregate
sales proceeds of up to $4,006,544 from time to time under this prospectus supplement and accompanying prospectus. The amount of proceeds
from this offering will depend upon the number of our common shares sold and the market price at which they are sold and will be reduced
by commissions and other expenses of this offering. There can be no assurance that we will be able to sell any shares under or fully utilize
the Sales Agreement as a source of financing. Because there is no minimum offering amount required as a condition to close this offering,
the net proceeds to us, if any, are not determinable at this time. We intend to use the net proceeds from this offering for general corporate
purposes which may include working capital, capital expenditures and research and development and manufacturing expenses.

The amounts and timing of our actual
expenditures will depend on numerous factors, including the amount of cash used in our operations. We therefore cannot estimate with certainty
the amount of net proceeds to be used for the purposes described above. We may find it necessary or advisable to use the net proceeds
for other purposes, and we will have broad discretion in the application of the net proceeds.

| S-9 |

### DIVIDEND POLICY
We have never declared nor paid dividends
on our common shares. We currently expect to retain future earnings, if any, for use in the operation and expansion of our business and
do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay dividends on our common shares
is subject to the discretion of our board of directors and will depend upon various factors, including, without limitation, our results
of operations and financial condition.

| S-10 |

### DILUTION
If you invest in our common shares,
your interest will be diluted immediately to the extent of the difference between the between the price per share you pay in this offering
and the as-adjusted net tangible book value per common share after this offering.

The net tangible book value of our common shares as of June 30, 2025 was approximately $12.1 million,
or approximately $1.73 per common share. Net tangible book value per share represents the amount of our total tangible assets less total
liabilities divided by the total number of our common shares outstanding as of June 30, 2025